Clinical trials: Incontinence, Urge
Overactive Bladder
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT01004315
- Testing
- KUC-7483, Tolterodine
- Where
- Japan
- Volunteers
- 750 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Urinary Incontinence
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge…
- Trial name
- NCT00147654
- Testing
- Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
- Where
- 95 sites in United States
- Volunteers
- 830 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Urinary Incontinence, Urge, Urinary Bladder, Overactive
INTIBIA Pivotal Study
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
- Conditions
- Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases
- Trial name
- NCT05250908
- Testing
- INTIBIA Therapeutic, INTIBIA Non-Therapeutic
- Where
- 22 sites in United States, Netherlands
- Volunteers
- 208 people
- Sponsor
- Coloplast A/S
Overactive Bladder
Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the study product, AOBO-001, when taken by adults with symptoms of overactive bladder. AOBO-001, is experimental, which means that the U. S.
- Trial name
- NCT01294982
- Testing
- AOBO-001
- Where
- 5 sites in United States
- Volunteers
- 66 people
- Sponsor
- American Oriental Bioengineering, Inc.
Overactive Bladder
Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence
Subjects with non-neurogenic over-active bladder will be enrolled. The hypothesis is that augmentation cystoplasty using an autologous neo-bladder construct will increase functional capacity and thereby reduce the number of…
- Trial name
- NCT00594139
- Testing
- Autologous neobladder construct
- Where
- United States
- Sponsor
- Tengion
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder Syndrome
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Idiopathic Detrusor Overactivity.
- Trial name
- NCT00335660
- Testing
- AV608
- Where
- 13 sites in Netherlands, United Kingdom
- Volunteers
- 62 people
- Sponsor
- Avera Pharmaceuticals
Urge Incontinence
A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.
The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence.
- Trial name
- NCT00269750
- Testing
- OROS® oxybutynin or Ditropan®
- Volunteers
- 100 people
- Sponsor
- Alza Corporation, DE, USA
Urinary Incontinence, Stress, Mixed Incontinence
Treatment for Stress and Mixed Urinary Incontinence and Vaginal Vault Prolapse
The primary objective of this study is to further evaluate the safety and effectiveness of the use of a sling device in women for stress and mixed urinary incontinence as well as vaginal vault prolapse.
- Conditions
- Urinary Incontinence, Stress, Mixed Incontinence, Vaginal Vault Prolapse
- Trial name
- NCT00223106
- Testing
- Vaginal Sling
- Where
- United States
- Volunteers
- 467 people
- Sponsor
- Medtronic - MITG
Urinary Urge Incontinence
Neuspera Revision Registry - Follow up Revision Experience and Evaluation of Device Outcomes Metrics
Single-arm study where subjects' responses to a questionnaire for the traditional Sacral Neuromodulation (SNM) devices will be compared to the responses regarding the Neuspera SNM System.
- Trial name
- NCT07383688
- Testing
- Neuspera Implantable Sacral Neuromodulation System
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Neuspera Medical, Inc.
Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI)
Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)
Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system.
- Conditions
- Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain, Urge Urinary Incontinence
- Trial name
- AURA-4X (NCT06885931)
- Testing
- Pudendal neuromodulation
- Where
- 7 sites in Belgium, Netherlands and 1 more
- Volunteers
- 86 people
- Sponsor
- Amber Therapeutics Ltd
Urinary Urge Incontinence
InterStim® Sacral Nerve Modulation Cycling Study
The study will assess the effects of different InterStim cycling settings on urinary urge incontinence.
- Trial name
- NCT01957137
- Testing
- InterStim® (Device Programming)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Urinary Incontinence, Stress Urinary Incontinence
Hybrid Fractional Laser Treatment for Symptoms of Urinary Incontinence
This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 lasers for improvement of symptoms of urinary incontinence.
- Conditions
- Urinary Incontinence, Stress Urinary Incontinence, Urge Incontinence
- Trial name
- NCT03180372
- Testing
- Hybrid Fractional Laser
- Where
- 5 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Sciton
Urge Urinary Incontinence, Urinary Frequency
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
The primary objective of the double-blind phase of the study is to compare the effects of two doses of oxybutynin gel to placebo gel.
- Trial name
- NCT00909181
- Testing
- Oxybutynin
- Where
- 55 sites in United States
- Volunteers
- 626 people
- Sponsor
- Antares Pharma Inc.
Urinary Incontinence
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
- Trial name
- NCT00127270
- Testing
- Darifenacin, Behavioral therapy
- Where
- 67 sites in United States
- Volunteers
- 395 people
- Sponsor
- Novartis
BPH, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
BE Technologies Mobile Uroflowmetry Validation Study
This research study is studying MenHealth Mobile Uroflowmetry as a diagnostic tool for LUTS (lower urinary tract symptoms), a group of conditions involving the bladder, urinary sphincter, urethra and the prostate.
- Conditions
- BPH, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms, BPH Without Urinary Obstruction, BPH Without Urinary Obstruction With Other Lower Urinary Tract Symptoms
- Trial name
- NCT04599283
- Testing
- MenHealth Uroflowmeter
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- BE Technologies Inc
Urinary Incontinence, Urinary Incontinence, Urge
Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD)
UCon is a medical device for treatment of the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder/bowel musculature…
- Conditions
- Urinary Incontinence, Urinary Incontinence, Urge, Fecal Incontinence, Fecal Incontinence With Fecal Urgency
- Trial name
- NCT06091566
- Testing
- UCon-Bar
- Where
- 3 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- InnoCon Medical
Overactive Bladder
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
Objective of this study was confirmation on non-inferiority and validation of similar safety profile of new anti-muscarinic medicinal product Uritos® (Imidafenacin) in comparison with other product from m-cholinergic antagonists…
- Trial name
- NCT03575702
- Testing
- Uritos®, Urotol®
- Where
- 11 sites in Russia
- Volunteers
- 300 people
- Sponsor
- R-Pharm
Urinary Bladder, Overactive
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active…
- Trial name
- TAURUS (NCT00688688)
- Testing
- Mirabegron, Tolterodine
- Where
- 308 sites in United States, Australia and 28 more
- Volunteers
- 2,792 people
- Sponsor
- Astellas Pharma Inc
Urinary Urge Incontinence
InterStim® Amplitude Study
This feasibility study will explore the effects of three different InterStim amplitude settings on overactive bladder symptoms (OAB).
- Trial name
- NCT03335761
- Testing
- InterStim Therapy
- Where
- 18 sites in United States, Belgium and 5 more
- Volunteers
- 97 people
- Sponsor
- MedtronicNeuro